Drugs such as Ozempic, Wegovy, and Mounjaro have upended the business of losing weight in America, a market that rang up $76B in sales in 2022, Andrea Petersen, Rolfe Winkler, and Sara Ashley O’Brien of The Wall Street Journal reports. Meanwhile, these new drugs are shaping up to be very successful for Novo Nordisk (NVO), which makes Ozempic and Wegovy, and Eli Lilly (LLY), which makes Mounjaro. Some industry players, such as WeightWatchers, are embracing the drugs and betting on them being crucial to the industry’s future. Others are taking the stance that diet and exercise programs are a natural alternatives, while focusing on the downsides of the medications. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Aeterna Zentaris says sales of Macrilen to be temporarily discontinued in U.S.
- Viking Therapeutics price target raised to $31 from $20 at BTIG
- Novo Nordisk reports PIONEER PLUS trial achieved primary endpoint
- Novo Nordisk Drops Its Insulin Prices
- Novo Nordisk to lower U.S. prices of several insulin products by up to 75%